Proteograph Product Suite And Thermo Fisher Partnership Will Open Markets

Shared on01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 9.67%

AnalystConsensusTarget has increased future PE multiple from 37.2x to 41.6x and decreased shares outstanding growth rate from -0.0% to -0.1%.